An open offer was made by Daiichi Sankyo to Zenotech Laboratories' shareholders at Rs 113.62 per share. This comes after it revised its earlier open offer price of Rs 160 per share.

Jayaram Chigrupati, MD, Zenotech Laboratories reacted to the development, "The agreement on open offer price was reached in July 2008. The agreed price was reached after shareholders filed a case post the Ranbaxy-Daiichi deal. The suit was withdrawn after Daiichi agreed to open offer price of Rs 160 per share."

Ranbaxy Laboratories CEO Malvinder Singh said that due to an import ban by the US authorities, his firm may shift some generic drug production from India to the US.

"We will transfer (production of) some products from India to America. Also, we are looking at making some acquisitions of manufacturing assets," said Mr Singh, at a media reception held by Japanese drugmaker Daiichi Sankyo.

Country’s largest pharmaceutical company, Ranbaxy Laboratories Limited, announced that it has acquired manufacturing facilities that have the approval from the U.S. Food and Drug Administration (FDA).

Speaking on this, Malvinder Singh, CEO Ranbaxy Laboratories said, “We will transfer (production of) some products from India to America. Also, we are looking at making some acquisitions of manufacturing assets.”

He added that apart from US, his company is also keeping its options open to buy FDA-approved facilities from other countries.

Aurobindo Pharma Ltd has received US Food and Drug Administration (USFDA) approval to manufacture and market generic versions of epilepsy drug levetiracetam in variable strengths.

Aurobindo will manufacture and market the tablet in dosages of 250 milligram, 500 mg, 750 mg and 1,000 mg and an oral solution in 100 mg per millilitre dose.

Levetiracetam is an anticonvulsant drug used for the treatment of epilepsy. It is S- enantiomer of etiracetam, structurally similar to the prototypical nootropic drug piracetam.

Jubilant Organosys, an integrated pharmaceutical industry player, has notified that its Bangalore-based subsidiary Jubilant Biosys Ltd, has entered into a drug discovery partnership with BioLeap, LLC, USA.

Under the relationship, BioLeap and Jubilant will integrate BioLeap's leading edge computational fragment based drug design platform with Jubilant's expertise in chemistry, biology and crystallography to offer a highly competitive preclinical drug development platform.

India-based Sun Pharmaceutical Industries Ltd has made announcement that the company along with its arm, has got first U.S. Food and Drug Administration sanction to market the generic version of a controlled substance in tablet form.

According to sources, the company is allowed to sell generic hydrocodone bitartate with acetaminophen in multiple strengths, which has a U.S. market size of $540 million for branded and generic versions.